AcuraStem has announced the members of its Scientific Board of Advisors comprised of PhDs, professors, tech entrepreneurs, and successful drug company veterans.
AcuraStem announces the addition of Monica Zhou, Ph.D. to their team as Principal Scientist. Zhou is in charge of industrializing the expansion of AcuraStem’s groundbreaking iNeuroRx platform and its multiple applications, ensuring their accuracy and efficiency.
AcuraStem Receives Fast-Track SBIR Grant for the Development of a Novel Small Molecule Therapy to Treat ALS
AcuraStem a fast-growing and innovative biotech company located in Monrovia, California, has been awarded a $3.7 million Small Business Innovation Research (SBIR) Fast-Track grant (#R44NS105156) by the National Institute of Neurological Disorders and Stroke (NINDS) to continue research for the development of a small molecule therapeutic, “AS2015”, focused on treating patients with the genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by expansion repeats in the gene C9ORF72.
AcuraStem is pleased to announce that it has been selected as a finalist in the 2018 Start-Up Stadium event at the BIO International Convention, June 4-7 in Boston.
The award recognizes Dr. Ichida's "pioneering work to convert patients’ skin cells into disease-affected neural cells, enabling them to screen thousands of drug-like compounds in search of potential therapeutics that could slow or stop ALS."